Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Financings

Marvel Biosciences Announces an Amendment to the Conversion Price for Marvel's Proposed Convertible Debenture Offering

By The Northwire Desk — AI Analysis Apr 13, 2026 · 17:31 MRVL · 0.165 Marvel Biosciences Corp.
MRVL · Price

Executive Summary

  • Marvel Biosciences Corp. has amended the conversion price for its previously announced non-brokered private placement of unsecured convertible debentures.

Key Details

  • Instrument: Unsecured convertible debentures.
  • Principal Amount: Up to $500,000.
  • Amended Conversion Price: $0.17 per Common Share.
  • Status: The offering remains subject to approval by the TSX Venture Exchange.
  • Other Terms: All other terms of the debentures and the offering remain unchanged from the announcement made on April 8, 2026.
Read the original news release →

More from Marvel Biosciences Corp.

Jun 08, 2026 · 07:00

Marvel Biosciences Receives Notice of Allowance for Australian Patent Application Covering Composition of Matter for its Lead Therapeutic Candidate MB-204

M&A / Property Apr 23, 2026 · 07:30

Marvel Biosciences Secures Funding and Patent Protection for Phase 1 Neurodevelopmental Candidate MB-204

Other Apr 17, 2026 · 16:30

Marvel Biosciences Closes Financing to Fuel Phase I Transition Amidst Patent Wins

Financings Apr 16, 2026 · 07:00

Marvel Biosciences Advances MB-204 Formulation Ahead of Phase I, But Data Integrity Concerns Linger

Other Apr 08, 2026 · 16:31

Small convertible debenture adds cash but raises dilution risk amid mounting debt

Financings Apr 07, 2026 · 07:30

New strategic financing trims Phase I cash burn, nudging MB‑204 toward first‑in‑human trial

Financings